The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

Official title:

Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT00864773
• Other study ID #: 2009-3-16
• Status: Unknown status
• Phase: N/A
• First received: March 18, 2009
• Last updated: March 18, 2009
• Start date: March 2009
• Est. completion date: March 2010

Study information

• Verified date: March 2009
• Source: Hallym University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 10
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of central serous chorioretinopathy

• Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography

• Presence of focal leaks at the level of the RPE on fluorescein angiography

Exclusion Criteria:

• Known side effects of systemic bevacizumab administration

• Have a significant cardiovascular or thromboembolic history or were pregnant

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

Intervention

Procedure:
• intravitreal injection with anterior paracentesis
0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hallym University Medical Center

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentrations of growth factors and inflammatory cytokines in Aqueous humor		at baseline
Secondary	Central macular thickness at optical coherence tomography		baseline, 1 month, 3 months, 6 months